1
|
Root-Bernstein R. Biased, Bitopic, Opioid–Adrenergic Tethered Compounds May Improve Specificity, Lower Dosage and Enhance Agonist or Antagonist Function with Reduced Risk of Tolerance and Addiction. Pharmaceuticals (Basel) 2022; 15:ph15020214. [PMID: 35215326 PMCID: PMC8876737 DOI: 10.3390/ph15020214] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2021] [Revised: 02/02/2022] [Accepted: 02/07/2022] [Indexed: 01/03/2023] Open
Abstract
This paper proposes the design of combination opioid–adrenergic tethered compounds to enhance efficacy and specificity, lower dosage, increase duration of activity, decrease side effects, and reduce risk of developing tolerance and/or addiction. Combinations of adrenergic and opioid drugs are sometimes used to improve analgesia, decrease opioid doses required to achieve analgesia, and to prolong the duration of analgesia. Recent mechanistic research suggests that these enhanced functions result from an allosteric adrenergic binding site on opioid receptors and, conversely, an allosteric opioid binding site on adrenergic receptors. Dual occupancy of the receptors maintains the receptors in their high affinity, most active states; drops the concentration of ligand required for full activity; and prevents downregulation and internalization of the receptors, thus inhibiting tolerance to the drugs. Activation of both opioid and adrenergic receptors also enhances heterodimerization of the receptors, additionally improving each drug’s efficacy. Tethering adrenergic drugs to opioids could produce new drug candidates with highly desirable features. Constraints—such as the locations of the opioid binding sites on adrenergic receptors and adrenergic binding sites on opioid receptors, length of tethers that must govern the design of such novel compounds, and types of tethers—are described and examples of possible structures provided.
Collapse
|
2
|
Harris DA, Park JM, Lee KS, Xu C, Stella N, Hague C. Label-Free Dynamic Mass Redistribution Reveals Low-Density, Prosurvival α1B-Adrenergic Receptors in Human SW480 Colon Carcinoma Cells. J Pharmacol Exp Ther 2017; 361:219-228. [PMID: 28196836 DOI: 10.1124/jpet.116.237255] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2016] [Accepted: 02/10/2017] [Indexed: 12/11/2022] Open
Abstract
Small molecules that target the adrenergic family of G protein-coupled receptors (GPCRs) show promising therapeutic efficacy for the treatment of various cancers. In this study, we report that human colon cancer cell line SW480 expresses low-density functional α1B-adrenergic receptors (ARs) as revealed by label-free dynamic mass redistribution (DMR) signaling technology and confirmed by quantitative reverse-transcriptase polymerase chain reaction analysis. Remarkably, although endogenous α1B-ARs are not detectable via either [3H]-prazosin-binding analysis or phosphoinositol hydrolysis assays, their activation leads to robust DMR and enhanced cell viability. We provide pharmacological evidence that stimulation of α1B-ARs enhances SW480 cell viability without affecting proliferation, whereas stimulating β-ARs diminishes both viability and proliferation of SW480 cells. Our study illustrates the power of label-free DMR technology for identifying and characterizing low-density GPCRs in cells and suggests that drugs targeting both α1B- and β-ARs may represent valuable small-molecule therapeutics for the treatment of colon cancer.
Collapse
Affiliation(s)
- Dorathy-Ann Harris
- Departments of Pharmacology (D.-A.H., J.-M.P., K.-S.L., C.X., N.S., C.H.) and Psychiatry and Behavioral Sciences (C.X., N.S.), University of Washington School of Medicine, Seattle, Washington
| | - Ji-Min Park
- Departments of Pharmacology (D.-A.H., J.-M.P., K.-S.L., C.X., N.S., C.H.) and Psychiatry and Behavioral Sciences (C.X., N.S.), University of Washington School of Medicine, Seattle, Washington
| | - Kyung-Soon Lee
- Departments of Pharmacology (D.-A.H., J.-M.P., K.-S.L., C.X., N.S., C.H.) and Psychiatry and Behavioral Sciences (C.X., N.S.), University of Washington School of Medicine, Seattle, Washington
| | - Cong Xu
- Departments of Pharmacology (D.-A.H., J.-M.P., K.-S.L., C.X., N.S., C.H.) and Psychiatry and Behavioral Sciences (C.X., N.S.), University of Washington School of Medicine, Seattle, Washington
| | - Nephi Stella
- Departments of Pharmacology (D.-A.H., J.-M.P., K.-S.L., C.X., N.S., C.H.) and Psychiatry and Behavioral Sciences (C.X., N.S.), University of Washington School of Medicine, Seattle, Washington
| | - Chris Hague
- Departments of Pharmacology (D.-A.H., J.-M.P., K.-S.L., C.X., N.S., C.H.) and Psychiatry and Behavioral Sciences (C.X., N.S.), University of Washington School of Medicine, Seattle, Washington
| |
Collapse
|
3
|
Abdel-Hamid IA, Andersson KE, Salonia A. Exploration of therapeutic targets for sexual dysfunctions: lessons learned from the failed stories. Expert Opin Ther Targets 2011; 15:325-40. [DOI: 10.1517/14728222.2011.551008] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
|